3 Things Investors Should Know About the Opioid Lawsuits Against Johnson & Johnson

Analysts are divided when it comes to Johnson & Johnson (NYSE:JNJ) stock. The medical device company experienced its share of ups and downs this year. It is currently one of many companies attempting to defend itself against ongoing opioid lawsuits. In August, an Oklahoma judge found Johnson & Johnson guilty of deceptive marketing practices and fined the company $572 million. The company allegedly marketed its opioid products as non-addictive, in spite of repeated warnings from the FDA.

The question for investors is, how important is this verdict and what will the ongoing lawsuit mean for JNJ stock? Here are three things you need to know about the opioid lawsuits. JNJ has been around for more than 130 years and is the largest healthcare company in the world. The company actively participates in nearly every aspect of the healthcare industry. That includes making consumer products, selling medical equipment, and making and distributing pharmaceuticals. So JNJ is a company that’s built to last. The opioid lawsuits will cause short-term problems for the company. JNJ stock has remained relatively flat over the last year and is up 2.4% in 2019. But the company should persevere in spite of its challenges.

Source: InvestorPlace

Related Articles:
- Why Dividend Growth Stocks Are Evil
- 4 Higher-Yielding Financial Services Stocks With Rising Dividends
- 5 Higher Yield Dividend Growth Stocks
- Successful Investors Take The Emotion Out
- 5 Under-Valued Dividend Growth Stocks